The risk for MACEs was higher among patients with HIV infection receiving abacavir- vs tenofovir-based ART regimens.

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

Trump administration funding cuts and dismantling of USAID force the focus to shift from elimination back to treatment.

The Benzinga Stock Whisper Index highlights five stocks that saw increased interest from readers during the week and a look ...

A new twice-yearly antiviral injection that can prevent HIV is likely to be approved soon in Australia. Making it affordable ...

On June 27th, celebrity and cultural advocate Miss Lawrence returned to Atlanta with Plated Purpose, an immersive dining ...

Baltimore's beloved live music tradition, Jazzy Summer Nights is well into its 25th and final season. This farewell season, ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company ...

The approval of Yeztugo is a momentous step in improving PrEP options available for people vulnerable to contracting ...